Journal CME - 2018 March
Back to Journal CME - 2018 March
Journal CME - 2018 March

Journal CME - 2018 March

Summary:

Fibrinolysis is a physiologic component of hemostasis that functions to limit clot formation. However, after trauma or surgery, excessive fibrinolysis may contribute to coagulopathy, bleeding, and inflammatory responses. Antifibrinolytic agents are increasingly used to reduce bleeding, allogeneic blood administration, and adverse clinical outcomes. Tranexamic acid is the agent most extensively studied and used in most countries. This review will explore the role of fibrinolysis as a pathologic mechanism, review the different pharmacologic agents used to inhibit fibrinolysis, and focus on the role of tranexamic acid as a therapeutic agent to reduce bleeding in patients after surgery and trauma.

CME Credit: 1.00 AMA PRA Category 1 Credit

Required Hardware / Software:
Adobe Acrobat Reader, Internet connection. Web browser version must have been released within the last three years.

Activity Release Date:
02/13/2018

Activity Expiration Date:
02/12/2021

  • List Price: $20.00
  • Member Price: Free
 
Want to save more?
Log into see if you qualify for a lower rate.
Members save $20.00 or more Join
Item Details:

Learning Objectives: After successfully completing this activity, the learner will be able to: 

- Explain the effects of plasminogen and plasmin on fibrinolysis and inflammatory response
- Evaluate the benefit of antifibrinolytics in a specific patient population
- Recognize the risk of...

Back to Journal CME - 2018 March
View More View Less
Back to Product Detail
There are not any reviews for this product.

Thank You Industry Supporters

Whose contributions allow the American Society of Anesthesiologists® to create world-class education and resources to improve patient care and outcomes.

Learn More